MIM
RARE icon

MetLife Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

MetLife Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Sell
5,672
-282
-5% -$6.35K ﹤0.01% 2461
2025
Q4 		$137K Buy
5,954
+204
+4% +$6.71K ﹤0.01% 2460
2025
Q3 		$173K Buy
5,750
+166
+3% +$4.98K ﹤0.01% 2398
2025
Q2 		$203K Buy
5,584
+123
+2% +$4.43K ﹤0.01% 2182
2025
Q1 		$198K Sell
5,461
-12
-0.2% -$499 ﹤0.01% 2210
2024
Q4 		$230K Sell
5,473
-208
-4% -$10.3K ﹤0.01% 2234
2024
Q3 		$316K Buy
5,681
+73
+1% +$3.72K ﹤0.01% 2038
2024
Q2 		$230K Buy
5,608
+829
+17% +$35.4K ﹤0.01% 2156
2024
Q1 		$223K Buy
4,779
+15
+0.3% +$708 ﹤0.01% 2143
2023
Q4 		$228K Buy
4,764
+608
+15% +$23.6K ﹤0.01% 2166
2023
Q3 		$148K Buy
4,156
+2
+0% +$79 ﹤0.01% 2370
2023
Q2 		$192K Buy
4,154
+698
+20% +$32.4K ﹤0.01% 2300
2023
Q1 		$139K Buy
3,456
+8
+0.2% +$343 ﹤0.01% 2419
2022
Q4 		$160K Sell
3,448
-82
-2% -$3.23K ﹤0.01% 2384
2022
Q3 		$146K Sell
3,530
-4
-0.1% -$206 ﹤0.01% 2475
2022
Q2 		$211K Buy
3,534
+67
+2% +$4.12K ﹤0.01% 2286
2022
Q1 		$252K Buy
+3,467
New +$241K ﹤0.01% 2213
2021
Q2 		– Sell
-23,550
Closed -$2.68M – 2479
2021
Q1 		$2.68M Sell
23,550
-1,332
-5% -$181K 0.02% 732
2020
Q4 		$3.44M Buy
24,882
+994
+4% +$118K 0.03% 556
2020
Q3 		$1.96M Sell
23,888
-1,069
-4% -$88.6K 0.02% 731
2020
Q2 		$1.95M Buy
24,957
+2,102
+9% +$139K 0.02% 724
2020
Q1 		$1.02M Sell
22,855
-1,607
-7% -$83.4K 0.01% 896
2019
Q4 		$1.04M Hold
24,462
– – 0.01% 1082
2019
Q3 		$1.05M Hold
24,462
– – 0.01% 1043
2019
Q2 		$1.55M Buy
24,462
+2,166
+10% +$138K 0.02% 921
2019
Q1 		$1.55M Buy
22,296
+2,069
+10% +$118K 0.02% 916
2018
Q4 		$879K Hold
20,227
– – 0.01% 1071
2018
Q3 		$1.54M Sell
20,227
-1,278
-6% -$104K 0.02% 959
2018
Q2 		$1.65M Buy
21,505
+1,383
+7% +$89.3K 0.02% 853
2018
Q1 		$1.03M Buy
20,122
+1,807
+10% +$91K 0.01% 995
2017
Q4 		$849K Buy
+18,315
New +$898K 0.01% 1099

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

MetLife Investment Management's RARE Position: Q1 2026 in Review

MetLife Investment Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 4.7% in Q1 2026, selling an estimated $6.35K and leaving 5,672 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #2461.

MetLife Investment Management first reported a position in RARE in Q4 2017 and has held it in 31 quarters since. The position peaked at $3.44M in Q4 2020. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • MetLife Investment Management held 5,672 shares of Ultragenyx Pharmaceutical worth $119K as of Q1 2026.
  • MetLife Investment Management sold 282 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $6.35K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2461 holding.
  • MetLife Investment Management first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and has held it in 31 quarters since.
  • MetLife Investment Management's Ultragenyx Pharmaceutical position peaked at $3.44M in Q4 2020.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.